Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

July 29, 2024

Primary Completion Date

June 27, 2025

Study Completion Date

June 27, 2025

Conditions
Metabolic Dysfunction-Associated Steatotic Liver DiseaseNon-alcoholic Fatty Liver DiseaseNonalcoholic Fatty Liver DiseaseLiver Disease
Interventions
DRUG

Efinopegdutide

SC injections in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg in all arms and 15 mg in the Efinopegdutide Q2W 15 mg arm

Trial Locations (39)

11096

Basil Clinical ( Site 0246), Inwood

20854

Velocity Clinical Research Rockville ( Site 0245), Rockville

28557

Lucas Research, Inc ( Site 0204), Morehead City

30720

Southeast Clinical Research Center ( Site 0223), Dalton

33012

AGA Clinical Trials ( Site 0274), Hialeah

33016

Neoclinical Research ( Site 0275), Hialeah

Floridian Clinical Research, LLC ( Site 0208), Miami Lakes

33033

Homestead Associates in Research, Inc. ( Site 0243), Homestead

33434

Excel Medical Clinical Trials ( Site 0268), Boca Raton

75230

Zenos Clinical Research ( Site 0240), Dallas

76012

Texas Clinical Research Institute ( Site 0230), Arlington

76710

Impact Research Institute ( Site 0227), Waco

77079

Houston Research Institute ( Site 0221), Houston

78215

American Research Corporation ( Site 0234), San Antonio

78229

Clinical Trials of Texas, LLC-Clinical Research ( Site 0252), San Antonio

Pinnacle Clinical Research-Clinical Research Coordination ( Site 0229), San Antonio

78404

Pinnacle Clinical Research-Corpus Christi ( Site 0267), Corpus Christi

78539

South Texas Research Institute ( Site 0226), Edinburg

78757

Pinnacle Clinical Research ( Site 0203), Austin

78759

Velocity Clinical Research, Austin ( Site 0201), Austin

84117

Olympus Family Medicine/CCT Research ( Site 0266), Holladay

84405

South Ogden Family Medicine/ CCT Research ( Site 0255), South Ogden

85224

The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 0, Chandler

85381

The Institute for Liver Health II dba Arizona Liver Health - Peoria ( Site 0224), Peoria

85712

Arizona Liver Health ( Site 0211), Tucson

85715

Del Sol Research Management, LLC ( Site 0209), Tucson

89101

The Machuca Foundation ( Site 0218), Las Vegas

89109

Excel Clinical Research, LLC ( Site 0200), Las Vegas

90247

Velocity Clinical Research, Gardena ( Site 0235), Gardena

90255

Velocity Clinical Research, Huntington Park ( Site 0210), Huntington Park

91105

California Liver Research Institute ( Site 0216), Pasadena

91405

Velocity Clinical Research, Panorama City ( Site 0228), Van Nuys

92025

Gastroenterology and Liver Institute ( Site 0263), Escondido

92120

Acclaim Clinical Research ( Site 0241), San Diego

92704

Velocity Clinical Research, Santa Ana ( Site 0250), Santa Ana

93012

Om Research LLC ( Site 0207), Camarillo

00726

San Juan Bautista School of Medicine - Clinical Research Unit ( Site 0104), Caguas

00909

Klinical Investigations Group-Clinical Research ( Site 0100), San Juan

Pan American Center for Oncology Trials - Ciudadela ( Site 0101), San Juan

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06482112 - Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016) | Biotech Hunter | Biotech Hunter